Chinese sequencing tech company GeneMind (真迈生物) has recently raised 400 million yuan in Series C financing, led by KingMed Diagnostics(金域医学) and Guoxin Investment(国鑫投资), with the later owned by Shanghai International Group(上海国际集团), an investment vehicle of Shanghai’s state-owned assets.
Shenzhen-based GeneMind is dedicated to R&D and manufacturing of molecular diagnostic devices with gene sequencer as the core business, such as the GenoLab M sequencing platform.
The new investment will be mainly used to increase the R&D of gene sequencing equipment and reagents and other new products, refine the existing products, expand the production capacity and speed up the declaration of the registration and certificate application.
